SG Americas Securities LLC Trims Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

SG Americas Securities LLC reduced its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 83.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,453 shares of the biotechnology company's stock after selling 28,025 shares during the period. SG Americas Securities LLC's holdings in Blueprint Medicines were worth $503,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in BPMC. American Century Companies Inc. raised its stake in shares of Blueprint Medicines by 5.2% in the third quarter. American Century Companies Inc. now owns 670,972 shares of the biotechnology company's stock worth $33,696,000 after purchasing an additional 33,243 shares during the last quarter. Diversified Trust Co raised its stake in shares of Blueprint Medicines by 2.9% in the third quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company's stock worth $563,000 after purchasing an additional 318 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Blueprint Medicines by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company's stock worth $78,000 after purchasing an additional 757 shares during the last quarter. Rafferty Asset Management LLC raised its stake in shares of Blueprint Medicines by 17.4% in the third quarter. Rafferty Asset Management LLC now owns 166,690 shares of the biotechnology company's stock worth $8,371,000 after purchasing an additional 24,693 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Blueprint Medicines by 0.6% in the third quarter. Vanguard Group Inc. now owns 5,967,143 shares of the biotechnology company's stock worth $299,670,000 after purchasing an additional 37,716 shares during the last quarter.

Insider Activity

In other news, insider Christopher K. Murray sold 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $100.00, for a total value of $500,000.00. Following the transaction, the insider now owns 24,495 shares in the company, valued at $2,449,500. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Christopher K. Murray sold 621 shares of the firm's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $93.65, for a total value of $58,156.65. Following the transaction, the insider now owns 36,374 shares in the company, valued at $3,406,425.10. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Christopher K. Murray sold 5,000 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $100.00, for a total value of $500,000.00. Following the transaction, the insider now owns 24,495 shares in the company, valued at approximately $2,449,500. The disclosure for this sale can be found here. Insiders have sold a total of 117,289 shares of company stock worth $10,361,913 over the last quarter. 3.88% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BPMC has been the subject of several research analyst reports. Wedbush restated an "outperform" rating and issued a $97.00 price objective on shares of Blueprint Medicines in a research note on Monday, February 5th. Wells Fargo & Company raised their price objective on Blueprint Medicines from $86.00 to $115.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 19th. Raymond James raised their target price on Blueprint Medicines from $85.00 to $100.00 and gave the stock a "strong-buy" rating in a report on Friday, December 22nd. HC Wainwright reaffirmed a "buy" rating and set a $85.00 target price on shares of Blueprint Medicines in a report on Monday, December 11th. Finally, Stifel Nicolaus raised their target price on Blueprint Medicines from $95.00 to $97.00 and gave the stock a "buy" rating in a report on Tuesday, January 9th. Four analysts have rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $85.43.

Blueprint Medicines Price Performance

BPMC traded up $0.97 during trading on Friday, hitting $91.65. The company's stock had a trading volume of 485,632 shares, compared to its average volume of 720,260. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60. Blueprint Medicines Co. has a twelve month low of $41.75 and a twelve month high of $101.00. The business's fifty day simple moving average is $87.66 and its 200 day simple moving average is $74.77. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of -10.96 and a beta of 0.63.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. The company had revenue of $71.96 million for the quarter, compared to analyst estimates of $67.34 million. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. Blueprint Medicines's quarterly revenue was up 85.5% compared to the same quarter last year. During the same period last year, the company earned ($2.65) earnings per share. On average, equities research analysts forecast that Blueprint Medicines Co. will post -5.42 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.